Biology and genetics of human neuroblastomas

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 2, 1997, Pages 93-101

  Brodeur, Garrett M ^a,b   Maris, John M ^a   Yamashiro, Darrell J ^a   Hogarty, Michael D ^a   White, Peter S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

1p36; Gene amplification; MYCN oncogene; Nerve growth factor (NGF); Neuroblastoma; Suppressor gene; Telomerase; TRK receptors

Indexed keywords

NERVE GROWTH FACTOR; TELOMERASE;

CAUSE OF DEATH; CHILD; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; DNA DETERMINATION; EARLY DIAGNOSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; REVIEW; STRUCTURE ACTIVITY RELATION; SUPPRESSOR GENE; TREATMENT PLANNING;

CHILD; CHILD, PRESCHOOL; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEUROBLASTOMA; TELOMERASE;

EID: 0030920743     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199703000-00001     Document Type: Review

References (105)

1. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hematol Oncol 1992; 14: 111-6.
2. Brodeur GM. Molecular pathology of human neuroblastomas. Semin Diagn Pathol 1994;11:118-25.
3. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 1995;31A:505-10.
4. Brodeur GM. Molecular basis for clinical heterogeneity: neuroblastoma as a model. In: Rose R, Hansen O, Larsen S, eds. Molecular basis for clinical heterogeneity: neuroblastoma as a model. Lyngby, Denmark: Bristol-Myers Squibb, 1996:45-54.
5. Evans AE, D'Angio GJ, Knudson AGJ, et al. Advances in neuroblastoma research 3. New York: Alan R. Liss, Inc., 1991.
6. Schwab M, Tonini GP, Benard J. Human neuroblastoma. Recent advances in clinical and genetic analysis. Chur, Switzerland: Harwood Academic Publishers, 1993.
7. Evans AE, Brodeur GM, D'Angio GJ, et al. Advances in neuroblastoma research 4. New York: Wiley-Liss, 1994.
8. Knudson AGJ, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972;24:514-22.
9. Knudson AGJ, Meadows AT. Developmental genetics of neuroblastoma. J Natl Cancer Inst 1976;57:675-82.
10. Kushner BH, Helson L. Monozygotic siblings discordant for neuroblastoma: etiologic implications. J Pediatr 1985;107:405-9.
11. Kushner BH, Gilbert F, Helson L. Familial neuroblastoma: case reports, literature review, and etiologic considerations. Cancer 1986;57: 1887-93.
12. Laureys G, Speleman F, Opdenakker G, et al. Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma. Genes Chrom Cancer 1990;2:252-4.
13. Biegel JA, White PS, Marshall HN, et al. Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet 1993;52:176-82.
14. White PS, Maris JM, Beltinger C, et al. A region of consistent deletion in neuroblastoma maps within 1p36.2-.3. Proc Nat Acad Sci USA 1995;92:5520-4.
15. Maris JM, Kyemba SM, Rebbeck TR, et al. Familial predisposition to neuroblastoma does not map to chromosome band 1p36. Cancer Res 1996;56:3421-5.
16. Maris JM, Chatten J, Meadows AT, et al. Familial neuroblastoma: new affected members and a further association with Hirschsprung disease. Med Pediatr Oncol 1997;28:1-5.
17. Franke F, Rudolph B, Christiansen H, et al. Tumour karyotype may be important in the prognosis of human neuroblastoma. J Cancer Res Clin Oncol 1986;111:266-72.
18. Hayashi Y, Hanada R, Yamamoto K, et al. Chromosome findings and prognosis in neuroblastoma. Cancer Genet Cytogenet 1986;29:175-7.
19. Kaneko Y, Kanda N, Maseki N, et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 1987;47:311-8.
20. Christiansen H, Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988;57:121-6.
21. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engt J Med 1984;311:231-5.
22. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma. J Clin Oncol 1991;9:581-91.
23. Brodeur GM, Sekhon GS, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer 1977;40:2256-63.
24. Brodeur GM, Green AA, Hayes FA, et al. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 1981;41:4678-86.
25. Gilbert F, Feder M, Balaban G, et al. Human neuroblastomas and abnormalities of chromosome 1 and 17. Cancer Res 1984;44:5444-9.
26. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 1989;41:153-74.
27. Fong CT, Dracopoli NC, White PS, et al. Loss of heterozygosity for chromosome 1p in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA 1989;86:3753-7.
28. Weith A, Martinsson T, Cziepluch C, et al. Neuroblastoma consensus deletion maps to 1p36.1-2. Genes Chrom Cancer 1989;1:159-66.
29. White PS, Kaufman BA, Marshall HN, et al. Use of the single-strand conformation polymorphism technique to detect loss of heterozygosity in neuroblastoma. Genes Chrom Cancer 1993;7:102-8.
30. Takeda O, Homma C, Maseki N, et al. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chrom Cancer 1994;10:30-9.
31. Schleiermacher G, Peter M, Michon J, et al. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma. Genes Chrom Cancer 1994;10:275-81.
32. Caron H, Peter M, van Sluis P, et al. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum Mol Genet 1995;4:535-9.
33. Martinsson T, Shoberg P-M, Hedborg F, et al. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res 1995;55:5681-6.
34. Van Roy N, Laureys G, Cheng NC, et al. 1;17 Translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chrom Cancer 1994;10:103-14.
35. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 1994;55:334-40.
36. Lahti JM, Valentine M, Xiang J, et al. Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nature Genet 1994;7:370-5.
37. Maris JM, Jensen SJ, Sulman EP, et al. Cloning, chromosomal localization, and physical mapping and genomic characterization of HKR3. Genomics 1996;35:289-98.
38. Beltinger CP, White PS, Maris JM, et al. Physical mapping and genomic structure of the human TNFR2 gene. Genomics 1996;35:94-100.
39. Enomoto H, Ozaki T, Takahashi E-I, et al. Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene 1994;9:2785-91.
40. Shafer BW, Mattei MG. The human paired domain gene PAX7 (Hup1) maps to chromosome 1p35-1p36.2. Genomics 1993;17:249-51.
41. Shapiro DN, Sublett JE, Li B, et al. The gene for PAX7, a member of the paired-box-containing genes, is localized on human chromosome arm 1p36. Genomics 1993;17:767-9.
42. Aso T, Lane WS, Conaway JW, et al. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995; 269:1439-43.
43. Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-6.
44. Lees JA, Saito M, Vidal M, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993;13: 7813-25.
45. Cheng JM, Hiemstra JL, Schneider SS, et al. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nature Genet 1993;4:191-4.
46. Caron H, van Sluis P, van Hoeve M, et al. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nature Genet 1993;4:187-90.
47. Suzuki T, Yokota J, Mugishima H, et al. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res 1989;49:1095-8.
48. Fong CT, White PS, Peterson K, et al. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992;52:1780-5.
49. Takayama H, Suzuki T, Mugishima H, et al. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene 1992;7:1185-9.
50. Srivatsan ES, Ying KL, Seeger RC. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chrom Cancer 1993;7:32-7.
51. Tsutsumi M, Yokota J, Kakizoe T, et al. Loss of heterozygosity on chromosomes 1p and 11p in sporadic pheochromocytoma. J Natl Cancer Inst 1989;81:367-70.
52. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995;24:215-21.
53. Imamura J, Bartram CR, Berthold F, et al. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 1993;53:4053-8.
54. Vogan K, Bernstein M, Brisson L, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res 1993;53:5269-73.
55. Komuro H, Hayashi Y, Kawamura M, et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res 1993;53:5284-8.
56. Beltinger CP, White PS, Sulman EP, et al. No CDKN2 mutations in neuroblastomas. Cancer Res 1995;55:2053-5.
57. The I, Murthy AE, Hannigan GE. et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nature Genet 1993;3:62-6.
58. Johnson MR, Look AT, DeClue JE, et al. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP-ras. Proc Natl Acad Sci USA 1993;90: 5539-43.
59. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
60. Kohl NE, Kanda N, Schreck RR, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35:359-67.
61. Schwab M, Varmus HE, Bishop JM, et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature 1984;308:288-91.
62. Brodeur GM, Seeger RC. Gene amplification in human neuroblastomas: basic mechanisms and clinical implications. Cancer Genet Cytogenet 1986;19:101-11.
63. Amler LC, Schwab M. Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently re-combined DNA. Mol Cell Biol 1989;9:4903-13.
64. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc 3 in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
65. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
66. Seeger RC, Wada R, Brodeur GM, et al. Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 1988;271:41-9.
67. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma: effect of genetic factors on prognosis and treatment. Cancer 1992;70:1685-94.
68. Brodeur GM, Pritchard J, Berthold F, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
69. Brodeur GM, Hayes FA, Green AA, et al. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res 1987;47:4248-53.
70. Maris JM, White PS, Beltinger CP, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-9.
71. Gehring M, Berthold F, Edler L, et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995;55:5366-9.
72. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30.
73. Nisen PD, Waber PG, Rich MA, et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 1988;80:1633-7.
74. Slavc I, Ellenbogen R, Jung W-H, et al. myc gene amplification and expression in primary human neuroblastoma. Cancer Res 1990;50: 1459-63.
75. Nakagawara A, Arima M, Azar CG, et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-8.
76. Cohn SL, Salwen H, Quasney MW, et al. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene 1990;5:1821-7.
77. Ballas K, Lyons J, Jannsen JWG, et al. Incidence of ras gene mutations in neuroblastoma. Eur J Pediatr 1988;147:313-4.
78. Ireland CM. Activated N-ras oncogenes in human neuroblastoma. Cancer Res 1989;49:5530-3.
79. Moley JF, Brother MB, Wells SA, et al. Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas and medullary thyroid cancers. Cancer Res 1991;51:1596-9.
80. Tanaka T, Slamon DJ, Shimoda H, et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 1988;48:1030-4.
81. Tanaka T, Slamon DJ, Shimada H, et al. A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. Cancer 1991;68:1296-302.
82. Hempstead BL, Martin-Zanca D, Kaplan DR, et al. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 1991;350:678-83.
83. Kaplan DR, Hempstead BL, Martin-Zanca D, et al. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991;252:554-8.
84. Klein R, Jing S, Nanduri V, et al. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991;65:189-97.
85. Klein R, Nanduri V, Jing S, et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991;66:395-403.
86. Lamballe F, Klein R, Barbacid M. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3. Cell 1991;66:967-79.
87. Squinto SP, Stitt TN, Aldrich TH, et al. trkB encodes a functional receptor for brain-derived neurotrophic factor and neurotrophin-3 but not nerve growth factor. Cell 1991;65:885-93.
88. Ip NY, Ibanez CF, Nye SH, et al. Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution, and receptor specificity. Proc Natl Acad Sci USA 1992;89:3060-4.
89. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847-54.
90. Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993;85:377-84.
91. Kogner P, Barbany G, Dominici C, et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993;53:2044-50.
92. Borrello MG, Bongarzone I, Pierotti MA, et al. TRK and RET protooncogene expression in human neuroblastoma specimens: high-frequency of trk expression in non-advanced stages. Intl J Cancer 1993;54:540-5.
93. Tanaka T, Hiyama E, Sugimoto T, et al. trkA gene expression in neuroblastoma. Cancer 1995;76:1086-95.
94. Nakagawara A, Azar CG, Scavarda NJ, et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759-67.
95. Acheson A, Conover JC, Fandi JP, et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 1995;374:450-3.
96. Kaplan DR, Matsumoto K, Lucarelli E, et al. Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Neuron 1993;11: 321-31.
97. TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995;55:1798-806.
98. Yamashiro DJ, Nakagawara A, Ikegaki N, et al. Expression of TrkC in favorable human neuroblastomas. Oncogene 1996;12:37-41.
99. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 1989;81:116-24.
100. Goldstein LJ, Fojo AT, Ueda K, et al. Expression of the multidrug resistance, MDR1, gene in neuroblastomas. J Clin Oncol 1990;8:128-36.
101. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
102. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-8.
103. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
104. Hiyama E, Hiyama K, Yokoyama T, et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1995;1:249-55.
105. Brodeur GM. Do the ends justify the means? Nature Med 1995; 1:203-5.